Interferon gamma is highly effective against orthotopically-implanted human pleural adenocarcinoma in nude mice

Anticancer Research

Volumn 16, Issue 5 A, 1996, Pages 2545-2551

  An, Zili ^a   Wang, Xiaoen ^a   Astoul, Philippe ^b   Danays, T ^c   Moossa, A R ^d   Hoffman, Robert M ^a,d  

^a ANTICANCER INC   (United States)

^b HÔPITAL DE LA CONCEPTION   (France)

^c BOEHRINGER INGELHEIM   (France)

^d UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

Author keywords

Cachexia; Interferon gamma; Metastasis; Nude mice; Pleural adenocarcinoma; Surgical orthotopic implautation

Indexed keywords

GAMMA INTERFERON; RECOMBINANT GAMMA INTERFERON;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER CELL CULTURE; CANCER INHIBITION; CANCER SURVIVAL; CANCER TRANSPLANTATION; CONTROLLED STUDY; CYANOSIS; DISEASE COURSE; DOSE RESPONSE; DRUG EFFICACY; DRUG TOLERABILITY; HUMAN; HUMAN CELL; HUMAN TISSUE; HYPOXIA; IMMOBILIZATION; INTRAPERITONEAL DRUG ADMINISTRATION; LUNG ADENOCARCINOMA; LUNG NON SMALL CELL CANCER; MALE; METASTASIS INHIBITION; MOUSE; NONHUMAN; PRIORITY JOURNAL;

ADENOCARCINOMA; ANIMALS; ANTINEOPLASTIC AGENTS; DRUG SCREENING ASSAYS, ANTITUMOR; HUMANS; IMMUNOTHERAPY; INTERFERON-GAMMA, RECOMBINANT; MALE; MICE; MICE, INBRED BALB C; MICE, NUDE; NEOPLASM TRANSPLANTATION; PLEURAL NEOPLASMS; RANDOM ALLOCATION; SURVIVAL RATE;

EID: 0029969075     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (46)

1. Fentimanj JS: Diagnosis and treatment of malignant effusion. Cancer Treat Rev 14: 107118, 1987.
2. Chemow, B et al Carcinimatous involvement of the pleura. Am J of Med 63: 695-702, 1977.
3. Rubin BY and Gupta SL: Differential efficacy of human type I and Type II interferon as antiviral and antiproliferative agents. Proc Natl Acad Sci USA 77: 5928-5932, 1980.
4. Agah R and Malloy B et al: Successful therapy of natural killer-resistant pulmonary metastasis by the synergism of γ-interferon with tumor necrosis factor and interleukin-2 in mice. Cancer Res 48: 2245-2248, 1988.
5. Sklarin NT and Chahinian AP et al: Augmentation of activity of cisdiamminedichloroplatinum (II) and mitomycin C by interferon in human malignant mesothelioma xenografts in nude mice. Cancer Res 4: 64-67, 1988.
6. Hand, A., and Pelin K et al: Interferon-alpha and interferon-gamma combined with chemotherapy: in vitro sensitivity studies in non-small cell lung cancer lines. Anti-Cancer Drugs 4: 365-368, 1993.
7. Hand AM and Husgafvel-Pursiainen K et al: Interferon-alpha and - gamma in combination with chemotherapeutic drugs: in vitro sensitivity studies in four human mesothelioma cell lines. Anti-Cancer Drugs, 3: 687-694, 1992.
8. Hansen RM and Borden EC et al: Current status of interferons in the treatment of cancer. Oncology 6: 19-24, 1992.
9. Aulitzky W and Gastl G et al: Successful treatment of metastatic renal cell carcinoma with a biological active dose of recombinant interferon-gamma. J Clin Oncol 7: 1875-1884, 1989.
10. Hoffman RM: Patient-like models of human cancer in mice. Current Perspectives on Molecular & Cellular Oncology 1(B): 311-326, 1992.
11. Hoffman RM: Orthotopic is orthodox: Why are orthotopic-transplant metastatic models different from all other models. J Cell Biochem 56: 1-3, 1994.
12. Fu X, Besterman JM, Monosov A and Hoffman RM: Models of human metastatic colon cancer in nude mice orthotopically constructed by using histologically-intact patient specimens. Proc Natl Acad Sci USA 88: 9345-9349, 1991.
13. Fu X, Guadagni F and Hoffman RM: A metastatic nude mice model of human pancreatic cancer constructed orthotopically from histologically-intact patient specimens. Proc Natl Acad Sci USA 89: 5645-5649, 1992.
14. Fu X and Hoffman RM: Human ovarian carcinoma metastatic models constructed in nude mice by orthotopic transplantation of histologically-intact patient specimens. Anticancer Res 13: 283-286, 1993.
15. Fu X, Le P, and Hoffman RM: A metastatic orthotopic transplant nude-mouse model of human patient breast cancer. Anticancer Res 13: 901-904, 1993.
16. Wang X, Fu X, Kubota T and Hoffman RM: A new patient-like metastatic model of human small-cell lung cancer constructed orthotopically with intact tissue via thoracotomy in immunodeficient mice. Anticancer Res 12: 1403-1406, 1992.
17. Astoul P, Colt HG, Wang X and Hoffman RM: A γpatient-likeγ nude mouse model of parietal human lung adenocarcinoma. Anticancer Res 14: 85-91, 1994.
18. Wang X, Fu X, and Hoffman RM: A patient-like metastasizing model of human lung adenocarcinoma constructed via thoracotomy in nude mice. Anticancer Res 12: 1399-1401, 1992.
19. Fu X, Theodorescu D, Kerbel RS and Hoffman RM: Extensive multiorgan metastasis following orthotopic onplantation of histologically-intact human bladder carcinoma tissue in nude mice. Int J Cancer 49: 938-939, 1991.
20. Furukawa T, Fu X, Kubota T, Watanabe M, Kitajima M and Hoffman RM: Nude mouse metastatic models of human stomach cancer constructed using orthotopic implantation of histologically-intact tissue. Cancer Res 53: 1204-1208, 1993.
21. Boyd MR and Paull KD: Some practical considerations and applications of the National Cancer Institute in vitro anticancer drug discovery screen. Drug Development Research 34: 91-109, 1995.
22. Astoul P, Colt HG, Wang X and Hoffman RM: A "patient-like" nude mouse metastatic model of advanced human pleural cancer. J Cellular Biochem 56: 9-15, 1994.
23. Trinchieri G, and Perussia B: Immune interferon: A pleotropic lymphokine with multiple effects. Immunol. Today 6: 131-136, 1985.
24. Balkwill FR and Watling D et al: Inhibition by lymphoblastoid interferon of growth of cells derived from the human breast. Int J Cancer 22: 258-265, 1978.
25. Balkwill FR and Mowshowitz, S et al: Positive interactions between interferon and chemotherapy due to direct tumor action rather than effects on host drug metabolizing enzymes. Cancer Res 44: 5249-5255, 1984.
26. Talmadge JE, and Herberman RB et al: Hyporesponsiveness to augmentation of murine natural killer cell activity in different anatomical compartments by multiple injections of various immunomodulators including recombinant interferons and interleukin 2. J Immunol 135: 2483-2491, 1985.
27. Varesio L and Blasi E et al: Potent activation of mouse macrophages by recombinant interferon-γ. Cancer Res 44: 4465-4469, 1984.
28. Talmadge JE and Tribble HR et al: Immunomodulatory and immunotherapeutic properties of recombinant γ-interferon and recombinant tumor necrosis factor in mice. Cancer Res 47: 2563-2570, 1987.
29. Talmadge JE and Phillips H et al: Systemic preclinical study on the therapeutic properties of recombinant human interleukin 2 for the treatment of metastatic diseases. Cancer Res 47: 5725-5732, 1987.
30. Garnick MB and Reich SD et al: Phase I/I1 study of recombinant interferon- gamma in renal cell carcinoma L Urol 139: 251-255, 1988.
31. D'Aquisto R, Markman M and Hakes T et al: A phase I trial of intraperitoneal recombinant gamma-interferon in advanced ovarian carcinoma. J Clin Oncol 6: 689-695, 1988.
32. Allavena P and Peccatori, F et al: Intraperitoneal recombinant gamma-interferon in patients with recurrent ascitic ovarian carcinoma: Modulation of cytotoxicity and cytokine production in tumor-associated effectors and of major histocompatibility antigen expression on tumor cells. Cancer Res 50: 7318-23, 1990.
33. Ernstoff MS, Reich S, Nishoda Y et al: Immunological assessment of melanoma patients treated with recombinant interferon gamma (rIFN-gamma, Biogen, INc, Cambridge, MA) in a phase I/II trial. Immunology 26: 280-286, 1985.
34. Maluish EA, and Urba WJ et al: The determination of an immunologically active dose of interferon-gamma in patients with melanoma. J Clin Oncol 6: 434-445, 1988.
35. Boutin C Viallat JR et al Activity of intrapleural recombinant gamma-interferon in malignant mesothelioma. Cancer 67: 2033-2037, 1991.
36. Richtsmeier WJ and Koch WM: Phase I-II study of advanced head and neck squamous cell carcinoma patients treated with recombinant human interferon gamma. Archives of Otolaryngology - Head and Neck Surgery 116: 1271-7, 1990.
37. Yoshida T and Okazaki N: Phase II trial of high dose recombinant gamma-interferon in advanced hepatocellular carcinoma. European J of Cancer 26: 545-6, 1990.
38. Habif DV and Ozello L et al: Regression of skin recurrences of breast carcinomas treated with intralesional injections of natural interferons alpha and gamma. Cancer Investigation 13: 165-172, 1995.
39. Bitran JD and Green, M et al: A phase II study of recombinant interferon-gamma following combination chemotherapy for patients with extensive small cell lung cancer. Am J Clin Oncol 18: 67-70, 1995.
40. Jett JR and Maksymiuk AW et al: Phase III trial of recombinant interferon gamma in complete responders with small-cell lung cancer. J Clin Oncol 12: 2321-2326, 1994.
41. Kleinerman ES and Kurzrock R et al: Activaton or suppression of the tumoricidal properties of monocytes from cancer patients following treatment with human recombinant gamma-interferon. Cancer Res 46: 5401-5405, 1986.
42. Weiner CM and Steplewski Z et al: Divergent dose-related effects of gamma-interferon therapy on in vitro antibody-dependent cellular and non-specific cytotoxicity by human peripheral blood monocytes. Cancer Res 48: 1042-1046, 1988.
43. Wang X, Fu X and Hoffman RM: A new patient-like metastatic model of human lung cancer constructed orthotopically with intact tissue via thoractomy in immunodeficient mice. Int J Cancer 51: 992-995, 1992.
44. Astoul P, Colt HG, Wang X and Hoffman RM: Metastastic human pleural ovarian cancer model constructed by orthotopic implantation of fresh histologically-intact patient carcinoma in nude mice. Anticancer Res 13: 1999-2002, 1993.
45. Astoul P, Wang X and Hoffman RM: "Patient-like" nude and SCID mouse models of human lung and pleural cancer. Int J Oncology 3: 713-718, 1993.
46. Wang X, Fu X and Hoffman RM: Matrix metalloproteinase BB-94 (Batimastat) inhibits human colon tumor growth and spread in a patient-like orthotopic model in nude mice. Cancer Res 54: 4726-4728, 1994.